Literature DB >> 25201058

The practical management of refractory schizophrenia--the Maudsley Treatment REview and Assessment Team service approach.

K Beck1, R McCutcheon, M A P Bloomfield, F Gaughran, T Reis Marques, J MacCabe, S Selvaraj, D Taylor, O D Howes.   

Abstract

OBJECTIVE: To describe a practical approach to the community management of treatment-resistant schizophrenia (TRS).
METHOD: A descriptive review of an approach to the assessment and management of patients with TRS, including the community titration of clozapine treatment, and a report of the management recommendations for the first one hundred patients assessed by the Treatment REview and Assessment Team (TREAT).
RESULTS: The standardized model for the community assessment, management and titration of clozapine is described. To date, 137 patients have been referred to this service and 100 patients (72%) attended for assessment. Of these, 33 have been initiated on clozapine while fifteen have had clozapine recommended but have not wished to undertake clozapine treatment. Other management options recommended have included augmentation strategies and long-acting injectable antipsychotics.
CONCLUSION: The service had increased the number of patients receiving community assessment and initiation of clozapine by five-fold relative to the rate prior to the establishment of the service. The large number of referrals and high attendance rate indicates that there is clinical demand for the model. Systematic evaluation is required to determine the clinical and cost-effectiveness of this model and its potential application to other clinical settings.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  antipsychotics; clozapine; community; health service; schizophrenia; treatment

Mesh:

Substances:

Year:  2014        PMID: 25201058     DOI: 10.1111/acps.12327

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  15 in total

1.  Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study.

Authors:  Euitae Kim; Oliver D Howes; Mattia Veronese; Katherine Beck; Seongho Seo; Jin Woo Park; Jae Sung Lee; Yun-Sang Lee; Jun Soo Kwon
Journal:  Neuropsychopharmacology       Date:  2016-11-18       Impact factor: 7.853

2.  Medication Gaps and Antipsychotic Polypharmacy in Previously Hospitalized Schizophrenia Patients: An Electronic Cohort Study in Three Canadian Provinces.

Authors:  Evyn Peters; Arash Shamloo; Rohit J Lodhi; Gene Marcoux; Kylie Jackson; Shawn Halayka; Lloyd Balbuena
Journal:  Front Psychiatry       Date:  2022-06-15       Impact factor: 5.435

3.  A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia.

Authors:  C U Correll; Ofer Agid; Benedicto Crespo-Facorro; Andrea de Bartolomeis; Andrea Fagiolini; Niko Seppälä; Oliver D Howes
Journal:  CNS Drugs       Date:  2022-06-27       Impact factor: 6.497

4.  Optimising treatment of schizophrenia: the role of adjunctive fluvoxamine.

Authors:  Siobhan Gee; Oliver Howes
Journal:  Psychopharmacology (Berl)       Date:  2016-01-16       Impact factor: 4.530

5.  Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms.

Authors:  Robert McCutcheon; Katherine Beck; Michael A P Bloomfield; Tiago R Marques; Maria Rogdaki; Oliver D Howes
Journal:  J Psychopharmacol       Date:  2015-03-18       Impact factor: 4.153

6.  Targeting glutamate to treat schizophrenia: lessons from recent clinical studies.

Authors:  Katherine Beck; Daniel C Javitt; Oliver D Howes
Journal:  Psychopharmacology (Berl)       Date:  2016-05-23       Impact factor: 4.530

7.  Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland.

Authors:  Oddur Ingimarsson; James H MacCabe; Magnús Haraldsson; Halldóra Jónsdóttir; Engilbert Sigurdsson
Journal:  BMC Psychiatry       Date:  2016-12-12       Impact factor: 3.630

Review 8.  Brain-imaging studies of treatment-resistant schizophrenia: a systematic review.

Authors:  Elias Mouchlianitis; Robert McCutcheon; Oliver D Howes
Journal:  Lancet Psychiatry       Date:  2016-03-04       Impact factor: 27.083

Review 9.  Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life.

Authors:  Cristiana Montemagni; Tiziana Frieri; Paola Rocca
Journal:  Neuropsychiatr Dis Treat       Date:  2016-04-19       Impact factor: 2.570

10.  Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia.

Authors:  R McCutcheon; K Beck; E D'Ambrosio; J Donocik; C Gobjila; S Jauhar; S Kaar; T Pillinger; T Reis Marques; M Rogdaki; O D Howes
Journal:  Acta Psychiatr Scand       Date:  2017-10-26       Impact factor: 6.392

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.